Chairman - Andrew Allars
Andy is CEO of Wyvern Asset Management which invests in spin-out opportunities from the Universities of Bristol and Southampton. He is also Managing Partner of venture consultancy, Anauel LLP. Andy entered the venture capital industry in 1990 and was until 2004, Head of Life Sciences at Prelude Ventures Limited, a specialist venture capital investor in early stage technology companies. During his time at Prelude he was closely involved in several successful start up bioscience companies including Acambis plc (now part of Sanofi), Quadrant Healthcare plc (now part of Vectura plc), Danby Medical Limited (now part of Baxter Inc) and Oxford Biomedica plc
Head of Life Sciences, IP Group plc - Mark Warne
Mark has been with IP Group since 2008 developing and commercialising healthcare technology innovations primarily from research intensive universities. Since 2012 he has led IP Group’s life sciences team and is a member of its therapeutics investment committee. Mark currently represents IP Group on the Boards of a number of its life science portfolio companies. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was managing director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.
Chief Scientific Officer and Director - Anthony Hollander
Anthony is a World leading scientist who pioneered the first tissue engineered trachea transplant to critical acclaim before founding Azellon. In 2010, the "Times" newspaper ranking of Britain's 100 most important scientists included him at number 39 on the list. He is President-elect of the International Cartilage Repair Society. Anthony is responsible for all scientific activities in the company and is also Head of the School of Cell Biology and Molecular Medicine at the University of Bristol.